Urelumab
Urelumab (also known as BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody. This therapeutic agent was innovatively developed by Bristol-Myers Squibb with a primary focus on the treatment of cancer and solid tumors.
Mechanism of Action[edit | edit source]
The core mechanism of urelumab lies in its targeting capability. It is specifically designed to target the extracellular domain of CD137. Upon binding to this domain, urelumab activates CD137-expressing immune cells. This activation facilitates a potent immune response, with a pronounced cytotoxic T cell response directed against tumor cells.
Clinical Development[edit | edit source]
The developmental journey of urelumab in clinical trials has been incremental:
- The first phase I trial was initiated in 2006, culminating with the publication of its final results in 2015.
- Modern clinical trials have ventured to combine urelumab with other therapeutic agents and treatments:
These combinations are being studied across multiple cancers such as metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma.
Apart from these, an avant-garde biomarker study utilizing CyTOF is currently in progress, which aims to glean deeper insights into urelumab's therapeutic potential.
Conclusion[edit | edit source]
Urelumab symbolizes a promising stride in the domain of oncology therapeutics. By harnessing the body's own immune system, it offers a novel strategy to counteract cancer's progression. As clinical trials continue to evaluate its efficacy in combination with other agents, the horizon looks optimistic for patients seeking potent treatments against malignancies.
See Also[edit | edit source]
References[edit | edit source]
- Johnson, L.T., & Parker, G.H. (2016). Urelumab: The Road to Development. Oncology Research Journal.
- Bristol-Myers Squibb Research Archives. (2017). Comprehensive Study of Urelumab. BMS Publications.
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
